Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02192554 · ClinicalTrials.gov registry record

Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo

A clinical trial of Nervous System Diseases and Mental Disorder, sponsored by Otsuka Pharmaceutical Development & Commercialization.

Completed
Registry status
450
Enrollment target
20
Study locations

NCT02192554 is a study of Nervous System Diseases and Mental Disorder that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 450 participants, above the 304-participant average among 23 other Nervous System Diseases trials with a reported enrollment target (48% higher). The trial reports 20 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02192554, a study of Nervous System Diseases and Mental Disorder, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.

COMPLETED
Registry status
450 participants
Enrollment target
20
Study locations

Study Summary

To follow-up on the safety of subjects who were previously treated in a double-blind trial of brexpiprazole.

Conditions Studied

Nervous System Diseases Mental Disorder Alzheimer's Type Agitation Associated With Alzheimer's Disease

Study Locations (20)

Florida

  • - Bradenton
  • - Hialeah
  • - Hialeah
  • - Miami
  • - Miami
  • - Miami
  • - Miami
  • - Miami Springs
  • - North Miami
  • - Orange City
  • - Sarasota

California

  • - Costa Mesa
  • - Lakewood
  • - Orange
  • - Redlands

Georgia

  • - Atlanta
  • - Suwanee

Alabama

  • - Tuscaloosa

Massachusetts

  • - Quincy

Missouri

  • - St Louis

Trial Details

FieldValue
Enrollment Target 450 participants
Start Date 2014-06
Est. Completion 2017-05

Sponsor

Otsuka Pharmaceutical Development & Commercialization

221 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02192554

The ClinicalTrials.gov registry entry for NCT02192554 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 450 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 304-participant average among 23 other Nervous System Diseases trials with a reported enrollment target (48% higher). The listed sponsor is Otsuka Pharmaceutical Development & Commercialization, which has 221 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Nervous System Diseases appearing as the primary indexed condition, and to 0 interventions.

NCT02192554 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Florida, California, Georgia.

Frequently Asked Questions

What is clinical trial NCT02192554 about?

NCT02192554 is a clinical study titled "Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo". To follow-up on the safety of subjects who were previously treated in a double-blind trial of brexpiprazole.

What is the current status of trial NCT02192554?

This trial is currently completed. The enrollment target is 450 participants. The study started on 2014-06. Estimated completion is 2017-05.

What conditions does trial NCT02192554 study?

This clinical trial studies the following conditions: Nervous System Diseases, Mental Disorder, Alzheimer's Type, Agitation Associated With Alzheimer's Disease.

Who is sponsoring clinical trial NCT02192554?

This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02192554 being conducted?

This trial has 20 study locations across Alabama, California, Florida, Georgia, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Nervous System Diseases

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Nervous System Diseases

All registered trials for this condition

Mental Disorder

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.